Crossmark Global Holdings’s Exact Sciences EXAS Stock Holding History

Crossmark Global Holdings’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,487	Closed	-$253K	–	1254
2025 Q4	$253K	Buy	+2,487	New	+$200K	﹤0.01%	1096
2018 Q4	–	Sell	-2,793	Closed	-$220K	–	1445
2018 Q3	$220K	Buy	+2,793	New	+$182K	0.01%	1498

Other funds holding EXAS

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PRS

Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return

PWMAG

Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.46B AUM 22.77% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Crossmark Global Holdings's EXAS Position: Q1 2026 in Review

Crossmark Global Holdings sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 2,487 shares — an estimated $253K sold.

Crossmark Global Holdings first reported a position in EXAS in Q3 2018 and held it in 2 quarters. The position peaked at $253K in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

Crossmark Global Holdings reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
Crossmark Global Holdings sold 2,487 Exact Sciences shares in Q1 2026, an estimated $253K.
Crossmark Global Holdings first reported a position in Exact Sciences in Q3 2018 and held it in 2 quarters.
Crossmark Global Holdings's Exact Sciences position peaked at $253K in Q4 2025.
7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Crossmark Global Holdings's 13F filing for Q1 2026, filed 11 May 2026.